Atrial Fibrillation Clinical Trials

• Male or non-pregnant female aged ≥18 years

• Documented non-valvular AF (paroxysmal, persistent, or permanent)

• High risk of stroke or systemic embolism, defined as CHA2DS2-VASc score of ≥ 3

• Has an appropriate rationale to seek a non-pharmacologic alternative to long-term oral anticoagulation

• Deemed by the site investigator to be suitable for short term oral anticoagulation therapy but deemed less favorable for long-term oral anticoagulation therapy.

• Deemed appropriate for LAA closure by the site investigator and a clinician not a part of the procedural team using a shared decision-making process in accordance with standard of care

• Able to comply with the protocol-specified medication regimen and follow-up evaluations

• The subject (or legally authorized representative, where allowed) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate institutional review board (IRB)/Regional Ethics Board (REB)/Ethics Committee (EC).